- $1.61bn
- $1.25bn
- $6.06bn
- 37
- 52
- 63
- 49
Annual income statement for Agilon Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,218 | 1,521 | 2,388 | 4,316 | 6,061 |
| Cost of Revenue | |||||
| Gross Profit | 196 | 164 | 294 | 308 | 218 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,275 | 1,894 | 2,499 | 4,548 | 6,353 |
| Operating Profit | -56.7 | -372 | -111 | -232 | -292 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -62.3 | -383 | -90.7 | -194 | -249 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -63.2 | -384 | -92.3 | -195 | -250 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -60.1 | -406 | -107 | -263 | -260 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -60.1 | -406 | -107 | -263 | -260 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.165 | -1.01 | -0.213 | -0.477 | -0.596 |
| Dividends per Share |